- OncoSec Medical (NASDAQ:ONCS) has developed a new, propriety technology to potentially treat pancreatic, liver and other difficult to treat visceral lesions through the direct delivery of plasmid-based interleukin-12 (IL-12) with a new Visceral Lesions Applicator (VLA).
- The company's new technology was published in a white paper titled "Parachuting Behind Enemy Lines: OncoSec's Attack on Visceral Tumors via Its New Visceral Lesion Applicator."
- The Company plans to introduce the new VLA, deploying its new product candidate, SPARK, and improved generator, APOLLO, in early 2020.
- Shares are up 6% premarket.